$Johnson & Johnson(JNJ)$ π ±οΈUΝ LΝ LΝ IΝ SΝ HΝπΊ
Looking to take a small equity position here at around $145.00 once Monday market opens. There is still some risk down to $137 to $138. I'll add if I see those numbers. So great to build a long term position.
π― $210 target early to mid 2026.
Mark Newton @ Fundstrat likes JNJ π
Source: MarketBeat
Analysts Set New Price Targets
A number of brokerages have recently weighed in on JNJ. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 16th. Wolfe Research started coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an "outperform" rating and a $190.00 price target for the company. Citigroup cut their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research note on Wednesday, December 11th. Finally, Guggenheim upped their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a report on Wednesday, November 6th. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $174.73.
The firm has a market capitalization of $349.23 billion, a PE ratio of 20.99, a P/E/G ratio of 2.52 and a beta of 0.51. The company's fifty day simple moving average is $153.32 and its 200-day simple moving average is $156.19. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson's quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.66 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.42%. Johnson & Johnson's dividend payout ratio (DPR) is presently 71.78%.
Insider Activity
In related news, Director Mark A. Weinberger purchased 1,000 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a β increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.16% of the company's stock.
Hedge Funds Weigh In On Johnson & Johnson
A number of institutional investors and hedge funds have recently added to or reduced their stakes in JNJ. Summit Wealth Partners LLC grew its holdings in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company's stock worth $1,463,000 after purchasing an additional 61 shares during the last quarter. Powers Advisory Group LLC raised its stake in shares of Johnson & Johnson by 0.6% in the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock valued at $1,538,000 after acquiring an additional 61 shares during the last quarter. Citizens & Northern Corp boosted its holdings in shares of Johnson & Johnson by 3.5% in the 2nd quarter. Citizens & Northern Corp now owns 1,884 shares of the company's stock worth $275,000 after acquiring an additional 63 shares in the last quarter. Eagle Wealth Strategies LLC increased its holdings in Johnson & Johnson by 2.8% during the 3rd quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company's stock valued at $372,000 after purchasing an additional 63 shares in the last quarter. Finally, Pine Harbor Wealth Management LLC raised its position in Johnson & Johnson by 1.9% in the 2nd quarter. Pine Harbor Wealth Management LLC now owns 3,472 shares of the company's stock valued at $507,000 after purchasing an additional 64 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.
@Tiger_comments @Daily_Discussion @TigerPM @TigerStars @TigerPicks @TigerGPT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Sorry! I can't answer this question.
Love Johnson products π Looks like a good long term stock BC. Thanks for sharing! π»π»π»
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?